Evelo Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 25.34 million compared to USD 29.86 million a year ago. Basic loss per share from continuing operations was USD 4.6 compared to USD 11.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.044 USD | -7.17% | -11.11% | -28.46% |
May. 02 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 25 | North American Morning Briefing : More Tech -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-28.46% | 900K | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- EVLO Stock
- News Evelo Biosciences, Inc.
- Evelo Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023